Author(s): Akyildiz M, Turan I, Ozutemiz O, Batur Y, Ilter T
Abstract Share this page
Abstract Upper gastrointestinal bleeding (UGIB) is a life-threatening complication of cirrhosis that develops from esophageal varices in almost 70\% of patients. The mortality rate from the bleeding episodes is reported to be 30\% [1-4]. Standard management of UGIB of cirrhotic patients is vasoactive therapy combined with endoscopic procedures such as endoscopic sclerotherapy and band ligation . Currently, it is reported that recombinant activated fVIIa (Novoseven, NovoNordisc) can correct the prothrombin time in decompensated cirrhotic patients and also can be used safely in Child's B and C cirrhotic patients with UGIB [6-8]. Herein, we describe the first case report in the literature of a cerebrovascular event after the administration of a single dose of fVIIa in a cirrhotic patient with esophageal variceal bleeding.
This article was published in Dig Dis Sci
and referenced in Journal of Anesthesia & Clinical Research